Pasireotide (SOM230) Demonstrates Efficacy and Safety in Patients with Acromegaly: A Randomized, Multicenter, Phase II Trial
Year: 2010
Type: article
Study designs: Randomized Controlled Trial, Clinical Trial
DOI: 10.1210/jc.2009-2272
Authors: S. Petersenn, J. Schopohl, A. Barkan, P. Mohideen, A. Colao, R. Abs, A. Buchelt, Y.-Y. Ho, K. Hu, A. J. Farrall, S. Melmed, B. M. K. Biller, the Pasireotide Acromegaly Study Group
Institutions: University of Duisburg-Essen, Ludwig-Maximilians-Universität München, Novartis (United States), University of Naples Federico II, University of Antwerp, Novartis (Switzerland), University of Michigan, Michigan Medicine, Western General Hospital, University of Edinburgh, Cedars-Sinai Medical Center, Massachusetts General Hospital
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2071232038